HIGHLIGHTS
- who: Cristiane Bergerot and collaborators from the Instituto Unity de Ensino e Pesquisa, Centro de Câncer de Brasília, Brasília, DF, Brazil Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea have published the research: Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma, in the Journal: (JOURNAL)
- what: The authors report HRQOL outcomes from a phase II trial (NCT03173560). The aim of this analysis was to evaluate HRQOL and disease symptoms as secondary endpoints from Study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.